Breaking News

Frontage Expands Development Services

April 3, 2013

Gains broader DEA license for pain therapeutics and controlled-substances

Frontage Laboratories has received approval to expand its U.S. Drug Enforcement Agency (DEA) license to include formulation development and manufacture of GMP clinical trial materials (CTM) for pain therapeutics and controlled-substances. For the expanded DEA license, Frontage upgraded its facilities, security, and personnel procedures at both of its Exton, PA sites.
 
Frontage supports companies developing DEA Schedules I–V controlled substances and provides analytical development and GMP analytical testing, clinical trial services and bioanalytical support of clinical and preclinical samples.
blog comments powered by Disqus
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO